News

Article

Pharmaceutical Technology

The Real Message Behind Commercial mRNA Products, April 2023 eBook
Volume2023 eBook
Issue 3
Pages: 6–11

Learning to Think at Lightspeed

Author(s):

Chris Spivey

Actions combatting the next pandemic must be diverse, reliable, and sustainable.

Ampoules vaccine from coronavirus with syringe 3d render illustration on white. | Image Credit: © mylisa - mylisa - Stock.adobe.com

mylisa - Stock.adobe.com

World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the United States’ goal to design, test, and review a new vaccine just 100 days after a pandemic declaration and to produce enough vaccines for the US and the world in 130 and 200 days. Past preparedness efforts have focused on innovation and reliability—culminating in the novel mRNA vaccines. Today, it’s important to consider diverse responses—and how the industry can make investments sustainable and “ready” for when an emergency happens.

Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook

About the author

Chris Spivey is editorial director of Pharmaceutical Technology.

Article details

Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 6–11

Citation

When referring to this article, please cite it as Spivey, C. Learning to Think at Lightspeed. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).

Articles in this issue
mRNA with 5'Cap | Image Credit: ©scienceDISPLAY - Stock.adobe.com
Stability in mRNA-LNP Formulations
Test tube with DNA moleculeon abstract background,3d rendering,conceptual image. | Image Credit:©Shuo - Stock.adobe.com
Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Ampoules vaccine from coronavirus with syringe 3d render illustration on white. | Image Credit: © mylisa - mylisa - Stock.adobe.com
Learning to Think at Lightspeed
Covid-19 vaccine clinical research. Abstract background with infographics and images, 3d illustration. | Image Credit: ©Paulista - Stock.adobe.com
Managing mRNA Instability
scienziato osserva provetta, campione di analisi, scienza futuristica | Image Credit:©xyz+ - Stock.adobe.com
The Role of Separation Techniques in the Analysis of mRNA Therapeutic Drug Substances and Drug Products
Single strand ribonucleic acid, RNA research and therapy | Image Credit:©nobeastsofierce - Stock.adobe.com
The Marriage of RNA and Mass Spectrometry
Ribosome as part of an biological cell constructing messenger rna molecules - 3d illustration | Image Credit: ©Christoph Burgstedt - Stock.adobe.com
Delivering on the Potential of mRNA Therapeutics
ampoules with Covid-19 vaccine on a laboratory bench. to fight the coronavirus / sars-cov-2 pandemic. | Image Credit: ©M.Rode-Foto - Stock.adobe.com
The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
July 25th 2025

EMA Approves Lower GWP Alternative for Inhalation Medicine

Susan Haigney
The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Magnifier with pills on blue background | Image Credit: © Pixel-Shot - stock.adobe.com
July 23rd 2025

Overcoming PK/PD Modeling Challenges

Cynthia A. Challener
Artificial intelligence and machine learning can help identify complex patterns.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Rueil-Malmaison, France - 13 août 2023: Siège social France de Bristol-Myers Squibb, entreprise pharmaceutique américaine née de la fusion entre Bristol-Myers Company et Squibb Corporation | Image Credit: © HJBC - stock.adobe.com
July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery
Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 21st 2025

FDA Appoints New CDER Director, George Tidmarsh

Susan Haigney
George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine program, has been appointed as the new director of the Center for Drug Evaluation and Research.